Responses to the Avandia panel have been all over the map, as cleverly noted on the Wall Street Journal's Health Blog. Avandia is “dead” (Forbes), or, perhaps worse, “now a Zombie” (BNET). By contrast, others thought the panel granted Avandia a “reprieve” (Wall Street Journal and that Avandia would now probably be allowed to stay on the market (Los Angeles Times, Pharmalot). All these views are ...

Read more...

I have a lot of diabetes patients and have been an avid user of the thiazolidinediones (TZD) class. There are many reasons to like the TZD's:

  • The older, generic medicines like metformin and sulfonylureas are known to fail over time. After 3 years, most patients on one of these drugs lose control of their blood sugar. In contrast, patients on TZD's maintain glycemic control (at least up to 4-5 years which ...

    Read more...

by Kristina Fiore More than one in 10 heart disease deaths may be attributable to diabetes, researchers say. In a meta-analysis of more than 100 studies, diabetes was associated with a twofold increased risk of the disease and was estimated to be accountable for 11% of vascular deaths, according to Nadeem Sarwar, MD, of the University of Cambridge in England, and colleagues. They reported their findings online in The Lancet and will present ...

Read more...

by Emily P. Walker An advisory panel voted 20-12 to recommend that the FDA allow rosiglitazone (Avandia) to stay on the market, but most panelists want to see the controversial diabetes drug carry tougher warnings on its label. Wednesday's vote marks the second time an FDA advisory panel has essentially endorsed rosiglitazone. In 2007, a panel voted that while the drug appears to carry a ...

Read more...

by Crystal Phend and Emily Walker Despite hints that the FDA may be leaning toward pulling rosiglitazone (Avandia) from the market, it's going to be a tough decision for the advisory committee slated to begin meeting on Tuesday, and things could still go either way, leading endocrinologists predict. "I think the FDA advisory committee is going to struggle with this because none of the data is conclusive," ...

Read more...

Whether I'm wearing my health policy hat or seeing patients in the office, one condition continues to surface as a source of concern and frustration. Diabetes, one of the nation's most serious and costly health burdens, now affects almost 25 million people in this country -- a conservative estimate. Another million new cases are diagnosed each year. Three years ago, the American Diabetes Association estimated the total diabetes cost in the U.S. ...

Read more...

Counting calories as part of health care reform—who knew? But apparently it’s there on page 455 of the health-care reform act, according to Marion Nestle, Professor of Nutrition at NYU, writing in the New England Journal of Medicine. There will now be a national effort at posting calorie counts in chain restaurants. There are many ways to improve the overall health of Americans, but tackling obesity is surely one of ...

Read more...

Bret Michaels is in critical condition from a subarachnoid hemorrhage. Bret Michaels has a subarachnoid hemorrhage, and what that meansI've been watching Celebrity Apprentice recently, and he comes across as a genuine person who, of course, has been raising awareness for Type 1 diabetes. As most people know, he has battled various diabetic complications on the show, and recently underwent an emergency appendectomy. What's his prognosis like? Not good, I'm ...

Read more...

Avandia continues to dominate cardiovascular-related news this week. Recently, the AHA and the ACC issued a highly detailed, thoughtful, though perhaps slightly over-diplomatic science advisory on TZDs and CV risk. Taking a completely opposite tack, GSK, in no mood to take prisoners, and apparently about to nominate itself for a Nobel Prize, issued a 30 page White Paper in response to the Senate report published on Saturday. At the core ...

Read more...

Originally published in MedPage Today An immediate-release form of the antidiabetic agent metformin has a dead fish odor that may cause patients to stop taking the drug, clinicians warned. Your metformin may smell like dead fish Metformin is known to cause adverse gastrointestinal effects such as diarrhea, nausea, vomiting, flatulence, distention, and abdominal pain. Those side effects "often necessitate discontinuing the drug," a group of physicians and pharmacists ...

Read more...

Most Popular